Aspirin-induced liver injury in a pediatric patient with Kawasaki disease
10.3760/cma.j.cn114015-20200112-00035
- VernacularTitle:阿司匹林致川崎病患儿肝损伤
- Author:
Yabing SHEN
1
;
Hongxia SU
1
Author Information
1. 甘肃医学院附属医院药剂科，平凉 744000
- Publication Type:Journal Article
- Keywords:
Aspirin;
Chemical and drug induced liver injury;
Mucocutaneous lymph node syndrome
- From:
Adverse Drug Reactions Journal
2020;22(11):648-649
- CountryChina
- Language:Chinese
-
Abstract:
A 28-month-old boy with Kawasaki disease received IV infusions of human immunoglobulin 15 g and sodium fructose diphosphate for injection 2.2 g once daily, and oral aspirin enteric-coated tablets 200 mg thrice daily. Two days after the treatments, the human immunoglobulin was stopped. Three days after the treatments, the dose of aspirin enteric-coated tablets was reduced to 75 mg once daily. The boy′s liver function was normal before the treatments. On the 5th day of treatments, laboratory tests showed that alanine aminotransferase (ALT) was 897 U/L, aspartate aminotransferase (AST) was 905 U/L, and lactate dehydrogenase (LDH) was 1 525 U/L. Drug-induced liver injury caused by aspirin enteric-coated tablets was considered. Aspirin was stopped and replaced by clopidogrel hydrogen sulfate, and glutathione and heparolysate were given for liver protection. Laboratory tests showed ALT 323 U/L, AST 66 U/L, and LDH 297 U/L 14 days later and ALT 27 U/L and AST 45 U/L 20 days later.
